FDA approves first Microsoft HoloLens augmented reality system for surgical use

The FDA has recently given 510(k) clearance to the OpenSight Augmented Reality System, the first augmented reality (AR) medical solution for Microsoft HoloLens cleared for use in pre-operative surgical planning.   

The technology projects 2D, 3D and 4D images of patients interactively by overlaying them onto the patient's body, according to a Novarad press release published Oct. 24.  

OpenSight specifically utilizes the Microsoft HoloLens headset that allows simultaneous visualization of the 3D patient images in AR and the actual patient and their real-world surroundings. The technique may decrease operative times and improve surgical planning and the understanding of anatomic relationships.  

“This is transformative technology that will unite preoperative imaging with augmented reality to improve the precision, speed and safety of medical procedures,” Wendell Gibby, MD, Novarad CEO and co-creator of OpenSight, said in the release. “This internal visualization can now be achieved without the surgeon ever making an incision, improving outcomes in a world of more precise medicine.” 

The technology also allows for a multi-user experience, as multiple HoloLens headsets can be worn among users for training or clinical purposes. A teaching version of the software is also available for medical students to perform virtual dissections on cadavers, according to the press release.  

""

A recent graduate from Dominican University (IL) with a bachelor’s in journalism, Melissa joined TriMed’s Chicago team in 2017 covering all aspects of health imaging. She’s a fan of singing and playing guitar, elephants, a good cup of tea, and her golden retriever Cooper.

Around the web

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Elucid's PlaqueIQ was trained to turn CCTA images into interactive 3D reports that help physicians visualize the presence of atherosclerosis.

Trimed Popup
Trimed Popup